QQ客服 官方微博 反馈留言

	Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study
	Bi, L.; Li, Y.; He, L.; Xu, H.; Jiang, Z.; Wang, Y.; Li, X.; Wei, W.; Gu, J.; Wang, G.
刊名	CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
	2019
卷号	37期号:2页码:227-234
关键词	tumour necrosis factor-alpha DMARD certolizumab pegol rheumatoid arthritis Chinese
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4547600
专题	山东大学
作者单位	1.Jilin Univ, China Japan Union Hosp, Changchun, Jilin, Peoples R China. 2.Peking Univ, Peoples Hosp, Beijing, Peoples R Chin
推荐引用方式 GB/T 7714	Bi, L.,Li, Y.,He, L.,et al. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,2019,37(2):227-234.
APA	Bi, L..,Li, Y..,He, L..,Xu, H..,Jiang, Z..,...&Wu, Z. 更多.(2019).Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,37(2),227-234.
MLA	Bi, L.,et al."Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study".CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 37.2(2019):227-234.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。